Supplementary

Table S1 Summary of included studies

References	Year	Country/region	N	Age (years)	Gender	Tumor type	Tumor stage	Cytokines	Assessment of sarcopenia
Scheede-Bergdahl *et al.* (25)	2012	Canada	83	Mean ± SD: 61.8±12.9	56.6% male; 43.4% female	Mixed	III–IV	IL-1β, IL-6, IL-8, and TNF-α	DXA
Reisinger *et al.* (32)	2016	The Netherlands	87	Mean ± SD: 65.6±11.9	64% male; 36% female	CRC	I–IV	IL-6	CT scan
He *et al.* (30)	2018	China	125	Median (range): 59 (19–87)	61.1% male; 39.9% female	CRC	I–III	CRC: IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-13, IL-15, IL-17, IL-12 P40, IL-12 P70, EGF, IFNα-2, IFNγ, IP-10, MCP-1, MCP-3, MIP-1α, MIP-1β, TNF-α, TNFβ, VEGF, FGF-2, TGF-α, FIT-3L, fractalkine, GRO, MDC, sCD40L, and sIL-2Rα	CT scan
Hou *et al.* (27)	2018	Taiwan	110	Median (range): 66 (37–85)	61.6% male; 38.4% female	Pancreatic	I–IV	IL-1β, IL-6, IL-8, and TNF-α	CT scan
Kays *et al.* (23)	2020	USA	217	Mean ± SD: 59.65±12.46	Not specified	CCRCC	I–IV	IL-6	CT scan
Hu *et al.* (28)	2021	Taiwan	114	Mean ± SD: 63.2±12.8	60% male; 40% female	CRC	I–IV	IL-23	CT scan
Tenuta *et al.* (26)	2021	Italy	47	Median (IQR): 67 (61–74)	57.4% male; 42.6% female	NSCLC	IV	IL-6, TNF-α and TGF-α	DXA
Aro *et al.* (29)	2022	Finland	222	≥70 (57.2%); <70 (42.8%)	52.7% male; 47.3% female	CRC	I–IV	IL-1R1, IL-4, IL-6, IL-7, CXCL8, IL-9, IL-12 P70, IFNγ, CXCL10, CCL2, CCL4, CCL11, and PDGF-BB	CT scan
Dalbeni *et al.* (22)	2023	Italy	93	Mean ± SD: 70±15	83.8% male; 16.2% female	HCC	I–IV	IL-6	CT scan
Lipshitz *et al.* (24)	2023	South Africa	40	Mean ± SD: 64.03±12.63	65% male; 35% female	Mixed tumors	IV	IL-6, IL-8 and TNF-α	BIA, HGS

Total number of patients: 1,138. SD, standard deviation; IL-1β, interleukin-1beta; IL-6, interleukin-6; IL-8, interleukin-8; TNF-α, tumor necrosis factor-alpha; DXA, dual-energy X-ray absorptiometry; CRC, colorectal cancer; CT, computed tomography; IL-1α, interleukin-1alpha; IL-1RA, interleukin-1 receptor antagonist; IL-2, interleukin-2; IL-3, interleukin-3; IL-4, interleukin-4; IL-5, interleukin-5; IL-7, interleukin-7; IL-9, interleukin-9; IL-10, interleukin-10; IL-13, interleukin-13; IL-15, interleukin-15; IL-17, interleukin-17; IL-12 P40, interleukin-12 p40; IL-12 P70, interleukin-12 p70; EGF, epidermal growth factor; IFNα-2, interferon alpha-2; IFNγ, interferon gamma; IP-10, interferon-gamma induced protein 10; MCP-1, monocyte chemoattractant protein-1; MCP-3, monocyte chemoattractant protein-3; MIP-1α, macrophage inflammatory protein-1alpha; MIP-1β, macrophage inflammatory protein-1beta; TNFβ, tumor necrosis factor beta; VEGF, vascular endothelial growth factor; FGF-2, fibroblast growth factor-2; TGF-α, tumor growth factor alpha; FIT-3L, FMS-like tyrosine kinase 3 ligand; GRO, growth-related oncogene; MDC, macrophage-derived chemokine; sCD40L, soluble CD40 ligand; sIL-2Rα, soluble interleukin-2 receptor alpha; CCRCC, clear cell renal carcinoma; IL-23, interleukin-23; IQR, interquartile range; NSCLC, non-small cell lung cancer; IL-1R1, interleukin 1 receptor type I; CXCL8, C-X-C motif chemokine ligand 8; CXCL10, C-X-C motif chemokine ligand 10; CCL2, chemokine ligand 2; CCL4, chemokine ligand 4; CCL11, chemokine ligand 11; PDGF-BB, platelet-derived growth factor subunit B; HCC, hepatocellular carcinoma; BIA, bioimpedance analysis; HGS, hand grip strength.

https://dx.doi.org/10.21037/atm-24-128